BML Capital Management’s Aclaris Therapeutics ACRS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $20.2M | Hold |
14,250,000
| – | – | 15.31% | 3 |
|
|
2025
Q1 | $21.8M | Hold |
14,250,000
| – | – | 17.65% | 2 |
|
|
2024
Q4 | $35.3M | Hold |
14,250,000
| – | – | 21.95% | 1 |
|
|
2024
Q3 | $16.4M | Buy |
14,250,000
+1,261,866
| +10% | +$1.45M | 9.64% | 4 |
|
|
2024
Q2 | $14.3M | Buy |
12,988,134
+3,592,200
| +38% | +$3.95M | 10.2% | 4 |
|
|
2024
Q1 | $11.7M | Buy |
9,395,934
+8,742,827
| +1,339% | +$10.8M | 7.68% | 5 |
|
|
2023
Q4 | $686K | Buy |
+653,107
| New | +$686K | 0.52% | 26 |
|